Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal ...

Reported positive results from the Expanded Access Protocol (NEXT), reinforcing NexoBrid's clinical and real-world benefits across 29 burn centers in the U.S. The study included 239 patients (215 ...

No one since the Beatles has done more to raise TM's pop-cultural profile than the director, who died in January and leaves ...

Discover Iovance's Q4'24 revenue growth, Proleukin's impact on Amtagvi's future, and how it faces competition like Obsidian's ...

“Health Minute” brings original health care and health policy reporting from the KFF Health News newsroom to the airwaves each week. (3/18) Here's today's health policy haiku: ...

Susan Cobb, a registered nurse and mother of a gymnast who was the victim of grooming by her coach, is speaking out against ...

The Clinical Trials Research Pillar in the Division of Biostatistics is at the forefront of innovative clinical trial design ...

HUTCHMED provides full year 2025 guidance for Oncology/Immunology consolidated revenue of $350 million to $450 million. HUTCHMED's work in 2025 and beyond will be supported by its strong balance sheet ...

A generic product cannot enter the market until the originator product’s IP has expired, but the development process can take ...

Learn the CUT online application process. The article explains how to apply on the CUT i-Enabler, required documents, how to ...